Clinical outcomes of high-flow nasal cannula oxygen therapy in acute heart failure patients with hypoxemia: A retrospective cohort study

Acute heart failure (AHF) is life-threatening medical condition requiring hospital admission and appropriate oxygen therapy. High flow nasal cannula oxygen therapy (HFNC) has gained its popularity in treatment of AHF, however, there were less studies have demonstrated the physiological efficacy of H...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2022-10, Vol.101 (43), p.e31124-e31124
Hauptverfasser: Tong, Xiao, Tong, Ningning, Yao, Feifei, Yan, Jing, Ci, Caizhe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e31124
container_issue 43
container_start_page e31124
container_title Medicine (Baltimore)
container_volume 101
creator Tong, Xiao
Tong, Ningning
Yao, Feifei
Yan, Jing
Ci, Caizhe
description Acute heart failure (AHF) is life-threatening medical condition requiring hospital admission and appropriate oxygen therapy. High flow nasal cannula oxygen therapy (HFNC) has gained its popularity in treatment of AHF, however, there were less studies have demonstrated the physiological efficacy of HFNC. Purpose of this study was to evaluated the physiological responses and clinical outcomes of HFNC by comparing with noninvasive positive pressure ventilation (NPPV) therapy. A retrospective cohort investigation was conducted at emergency intensive care unit (EICU) and cardiovascular center of our hospital from June 2019 to March 2022, AHF patients with hypoxemia were reviewed. According to the received oxygen therapy model, patients were divided into HFNC and NPPV groups. Demographic data, arterial blood gas (ABG) parameter, echocardiography findings, complications and other related variables were extracted and collected from the electronic medical records (EMRs) by well-trained investigators. Physiological responses and clinical outcomes within and between 2 groups were analyzed. Finally, 156 patients with a mean age of 69.3 ± 7.1 years were reviewed, there were 82 (52.6%) male and 74 (47.4%) female patients in the sample and 70 (44.9%) and 86 (55.1%) patients classified III and IV score were included in this study, 80 patients received HFNC and 76 underwent NPPV oxygen therapy. There were no significant differences of baseline characteristics for the 2 groups patients. Changes of left ventricular function parameters, ABG and clinical outcomes were all improved satisfactorily after 24 h medical interventions in both group, what’s more, patients underwent HFNC therapy could acquire a better amelioration when compared with NPPV groups ( P < .05). HFNC may be an ideal model for patients with AHF, particularly those with hypoxemia. HFNC therapy could significantly improve several objective parameters of physiological responses and clinical outcomes.
doi_str_mv 10.1097/MD.0000000000031124
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9622568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2731056040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4000-e874a9a9e27fd02dd9aa73bdfdf222754b34956b1cd2970e833f0d5ba292e02d3</originalsourceid><addsrcrecordid>eNpdkctu1TAQhi0EoofCEyAhL9mk-JY4ZoFUnZaL1IoNrC3HmZwYfOJgOz3NG_DYGE4pF29G8nz_PzP6EXpOyRklSr66vjgjfx6nlIkHaENr3lS1asRDtCGE1ZVUUpygJyl9IYRyycRjdMIbTpu25Rv0fevd5KzxOCzZhj0kHAY8ut1YDT4c8GRS6VkzTYs3ONyuO5hwHiGaecVuwsYuGfAIJmY8GOeXCHg22cGUEz64POJxncMt7J15jc9xhBxDmsFmdwPYhjEUXcpLvz5FjwbjEzy7q6fo89vLT9v31dXHdx-251eVFeXKClopjDIKmBx6wvpeGSN51w_9wBiTtei4UHXTUdszJQm0nA-krzvDFIPC81P05ug7L90eelsWjcbrObq9iasOxul_O5Mb9S7caNUwVjdtMXh5ZxDDtwVS1nuXLHhvJghL0kxySuqGCFJQfkRtOTpFGO7HUKJ_ZqivL_T_GRbVi783vNf8Dq0A4ggcgs8Q01e_HCDqEoLP4y-_WipWMcIYJawlVflpCP8BEEmq5A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2731056040</pqid></control><display><type>article</type><title>Clinical outcomes of high-flow nasal cannula oxygen therapy in acute heart failure patients with hypoxemia: A retrospective cohort study</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Tong, Xiao ; Tong, Ningning ; Yao, Feifei ; Yan, Jing ; Ci, Caizhe</creator><creatorcontrib>Tong, Xiao ; Tong, Ningning ; Yao, Feifei ; Yan, Jing ; Ci, Caizhe</creatorcontrib><description>Acute heart failure (AHF) is life-threatening medical condition requiring hospital admission and appropriate oxygen therapy. High flow nasal cannula oxygen therapy (HFNC) has gained its popularity in treatment of AHF, however, there were less studies have demonstrated the physiological efficacy of HFNC. Purpose of this study was to evaluated the physiological responses and clinical outcomes of HFNC by comparing with noninvasive positive pressure ventilation (NPPV) therapy. A retrospective cohort investigation was conducted at emergency intensive care unit (EICU) and cardiovascular center of our hospital from June 2019 to March 2022, AHF patients with hypoxemia were reviewed. According to the received oxygen therapy model, patients were divided into HFNC and NPPV groups. Demographic data, arterial blood gas (ABG) parameter, echocardiography findings, complications and other related variables were extracted and collected from the electronic medical records (EMRs) by well-trained investigators. Physiological responses and clinical outcomes within and between 2 groups were analyzed. Finally, 156 patients with a mean age of 69.3 ± 7.1 years were reviewed, there were 82 (52.6%) male and 74 (47.4%) female patients in the sample and 70 (44.9%) and 86 (55.1%) patients classified III and IV score were included in this study, 80 patients received HFNC and 76 underwent NPPV oxygen therapy. There were no significant differences of baseline characteristics for the 2 groups patients. Changes of left ventricular function parameters, ABG and clinical outcomes were all improved satisfactorily after 24 h medical interventions in both group, what’s more, patients underwent HFNC therapy could acquire a better amelioration when compared with NPPV groups ( P &lt; .05). HFNC may be an ideal model for patients with AHF, particularly those with hypoxemia. HFNC therapy could significantly improve several objective parameters of physiological responses and clinical outcomes.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000031124</identifier><identifier>PMID: 36316883</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Aged ; Cannula ; Female ; Heart Failure - complications ; Heart Failure - therapy ; Humans ; Hypoxia - complications ; Hypoxia - therapy ; Male ; Middle Aged ; Noninvasive Ventilation - adverse effects ; Observational Study ; Oxygen ; Respiratory Insufficiency - therapy ; Retrospective Studies</subject><ispartof>Medicine (Baltimore), 2022-10, Vol.101 (43), p.e31124-e31124</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4000-e874a9a9e27fd02dd9aa73bdfdf222754b34956b1cd2970e833f0d5ba292e02d3</cites><orcidid>0000-0002-0809-2603</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622568/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622568/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36316883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tong, Xiao</creatorcontrib><creatorcontrib>Tong, Ningning</creatorcontrib><creatorcontrib>Yao, Feifei</creatorcontrib><creatorcontrib>Yan, Jing</creatorcontrib><creatorcontrib>Ci, Caizhe</creatorcontrib><title>Clinical outcomes of high-flow nasal cannula oxygen therapy in acute heart failure patients with hypoxemia: A retrospective cohort study</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Acute heart failure (AHF) is life-threatening medical condition requiring hospital admission and appropriate oxygen therapy. High flow nasal cannula oxygen therapy (HFNC) has gained its popularity in treatment of AHF, however, there were less studies have demonstrated the physiological efficacy of HFNC. Purpose of this study was to evaluated the physiological responses and clinical outcomes of HFNC by comparing with noninvasive positive pressure ventilation (NPPV) therapy. A retrospective cohort investigation was conducted at emergency intensive care unit (EICU) and cardiovascular center of our hospital from June 2019 to March 2022, AHF patients with hypoxemia were reviewed. According to the received oxygen therapy model, patients were divided into HFNC and NPPV groups. Demographic data, arterial blood gas (ABG) parameter, echocardiography findings, complications and other related variables were extracted and collected from the electronic medical records (EMRs) by well-trained investigators. Physiological responses and clinical outcomes within and between 2 groups were analyzed. Finally, 156 patients with a mean age of 69.3 ± 7.1 years were reviewed, there were 82 (52.6%) male and 74 (47.4%) female patients in the sample and 70 (44.9%) and 86 (55.1%) patients classified III and IV score were included in this study, 80 patients received HFNC and 76 underwent NPPV oxygen therapy. There were no significant differences of baseline characteristics for the 2 groups patients. Changes of left ventricular function parameters, ABG and clinical outcomes were all improved satisfactorily after 24 h medical interventions in both group, what’s more, patients underwent HFNC therapy could acquire a better amelioration when compared with NPPV groups ( P &lt; .05). HFNC may be an ideal model for patients with AHF, particularly those with hypoxemia. HFNC therapy could significantly improve several objective parameters of physiological responses and clinical outcomes.</description><subject>Aged</subject><subject>Cannula</subject><subject>Female</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Hypoxia - complications</subject><subject>Hypoxia - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Noninvasive Ventilation - adverse effects</subject><subject>Observational Study</subject><subject>Oxygen</subject><subject>Respiratory Insufficiency - therapy</subject><subject>Retrospective Studies</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctu1TAQhi0EoofCEyAhL9mk-JY4ZoFUnZaL1IoNrC3HmZwYfOJgOz3NG_DYGE4pF29G8nz_PzP6EXpOyRklSr66vjgjfx6nlIkHaENr3lS1asRDtCGE1ZVUUpygJyl9IYRyycRjdMIbTpu25Rv0fevd5KzxOCzZhj0kHAY8ut1YDT4c8GRS6VkzTYs3ONyuO5hwHiGaecVuwsYuGfAIJmY8GOeXCHg22cGUEz64POJxncMt7J15jc9xhBxDmsFmdwPYhjEUXcpLvz5FjwbjEzy7q6fo89vLT9v31dXHdx-251eVFeXKClopjDIKmBx6wvpeGSN51w_9wBiTtei4UHXTUdszJQm0nA-krzvDFIPC81P05ug7L90eelsWjcbrObq9iasOxul_O5Mb9S7caNUwVjdtMXh5ZxDDtwVS1nuXLHhvJghL0kxySuqGCFJQfkRtOTpFGO7HUKJ_ZqivL_T_GRbVi783vNf8Dq0A4ggcgs8Q01e_HCDqEoLP4y-_WipWMcIYJawlVflpCP8BEEmq5A</recordid><startdate>20221028</startdate><enddate>20221028</enddate><creator>Tong, Xiao</creator><creator>Tong, Ningning</creator><creator>Yao, Feifei</creator><creator>Yan, Jing</creator><creator>Ci, Caizhe</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0809-2603</orcidid></search><sort><creationdate>20221028</creationdate><title>Clinical outcomes of high-flow nasal cannula oxygen therapy in acute heart failure patients with hypoxemia: A retrospective cohort study</title><author>Tong, Xiao ; Tong, Ningning ; Yao, Feifei ; Yan, Jing ; Ci, Caizhe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4000-e874a9a9e27fd02dd9aa73bdfdf222754b34956b1cd2970e833f0d5ba292e02d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Cannula</topic><topic>Female</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Hypoxia - complications</topic><topic>Hypoxia - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Noninvasive Ventilation - adverse effects</topic><topic>Observational Study</topic><topic>Oxygen</topic><topic>Respiratory Insufficiency - therapy</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tong, Xiao</creatorcontrib><creatorcontrib>Tong, Ningning</creatorcontrib><creatorcontrib>Yao, Feifei</creatorcontrib><creatorcontrib>Yan, Jing</creatorcontrib><creatorcontrib>Ci, Caizhe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tong, Xiao</au><au>Tong, Ningning</au><au>Yao, Feifei</au><au>Yan, Jing</au><au>Ci, Caizhe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of high-flow nasal cannula oxygen therapy in acute heart failure patients with hypoxemia: A retrospective cohort study</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2022-10-28</date><risdate>2022</risdate><volume>101</volume><issue>43</issue><spage>e31124</spage><epage>e31124</epage><pages>e31124-e31124</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Acute heart failure (AHF) is life-threatening medical condition requiring hospital admission and appropriate oxygen therapy. High flow nasal cannula oxygen therapy (HFNC) has gained its popularity in treatment of AHF, however, there were less studies have demonstrated the physiological efficacy of HFNC. Purpose of this study was to evaluated the physiological responses and clinical outcomes of HFNC by comparing with noninvasive positive pressure ventilation (NPPV) therapy. A retrospective cohort investigation was conducted at emergency intensive care unit (EICU) and cardiovascular center of our hospital from June 2019 to March 2022, AHF patients with hypoxemia were reviewed. According to the received oxygen therapy model, patients were divided into HFNC and NPPV groups. Demographic data, arterial blood gas (ABG) parameter, echocardiography findings, complications and other related variables were extracted and collected from the electronic medical records (EMRs) by well-trained investigators. Physiological responses and clinical outcomes within and between 2 groups were analyzed. Finally, 156 patients with a mean age of 69.3 ± 7.1 years were reviewed, there were 82 (52.6%) male and 74 (47.4%) female patients in the sample and 70 (44.9%) and 86 (55.1%) patients classified III and IV score were included in this study, 80 patients received HFNC and 76 underwent NPPV oxygen therapy. There were no significant differences of baseline characteristics for the 2 groups patients. Changes of left ventricular function parameters, ABG and clinical outcomes were all improved satisfactorily after 24 h medical interventions in both group, what’s more, patients underwent HFNC therapy could acquire a better amelioration when compared with NPPV groups ( P &lt; .05). HFNC may be an ideal model for patients with AHF, particularly those with hypoxemia. HFNC therapy could significantly improve several objective parameters of physiological responses and clinical outcomes.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>36316883</pmid><doi>10.1097/MD.0000000000031124</doi><orcidid>https://orcid.org/0000-0002-0809-2603</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2022-10, Vol.101 (43), p.e31124-e31124
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9622568
source Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Aged
Cannula
Female
Heart Failure - complications
Heart Failure - therapy
Humans
Hypoxia - complications
Hypoxia - therapy
Male
Middle Aged
Noninvasive Ventilation - adverse effects
Observational Study
Oxygen
Respiratory Insufficiency - therapy
Retrospective Studies
title Clinical outcomes of high-flow nasal cannula oxygen therapy in acute heart failure patients with hypoxemia: A retrospective cohort study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T16%3A03%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20high-flow%20nasal%20cannula%20oxygen%20therapy%20in%20acute%20heart%20failure%20patients%20with%20hypoxemia:%20A%20retrospective%20cohort%20study&rft.jtitle=Medicine%20(Baltimore)&rft.au=Tong,%20Xiao&rft.date=2022-10-28&rft.volume=101&rft.issue=43&rft.spage=e31124&rft.epage=e31124&rft.pages=e31124-e31124&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000031124&rft_dat=%3Cproquest_pubme%3E2731056040%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2731056040&rft_id=info:pmid/36316883&rfr_iscdi=true